Evidence map›Paper›PMID 26121081›Full record

ArticleJAMA neurology2015

Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.

Yakeel T Quiroz, Aaron P Schultz, Kewei Chen, Hillary D Protas, Michael Brickhouse, Adam S Fleisher, Jessica B Langbaum, Pradeep Thiyyagura, Anne M Fagan, Aarti R Shah and 13 more

Open access · greenAbstract read
In one paragraph

Article in JAMA neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Connectome-based predictive modeling of brain pathology and cognition in autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Early molecular events of autosomal-dominant Alzheimer's disease in marmosets with PSEN1 mutations.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 2 countries.

Yakeel T QuirozDepartment of Neurology, Massachusetts General Hospital, Boston2Department of Psychiatry, Massachusetts General Hospital, Boston3Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Ma.
Aaron P SchultzAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts.
Kewei ChenBanner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix8Department of Mathematics and Statistics, Arizona State University, Tempe.
Hillary D ProtasBanner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix.
Michael BrickhouseAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts9Frontotemporal Dementia Unit, Department of Neurology, Massachusetts General Hospital, Boston.
Adam S FleisherBanner Alzheimer's Institute, Phoenix, Arizona10Eli Lilly and Company, Indianapolis, Indiana11Department of Neurosciences, University of California, San Diego.
Jessica B LangbaumBanner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix.
Pradeep ThiyyaguraBanner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix.
Anne M FaganDepartment of Neurology, Washington University School of Medicine, St Louis, Missouri.
Aarti R ShahDepartment of Neurology, Washington University School of Medicine, St Louis, Missouri.
Martha MunizPsychology Department, Boston University, Boston, Massachusetts.
Joseph F Arboleda-VelasquezSchepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston15Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Claudia MunozGrupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia.
Gloria GarciaGrupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia.
Natalia Acosta-BaenaGrupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia.
Margarita GiraldoGrupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia.
Victoria TiradoGrupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia.
Dora L RamírezGrupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia.
Pierre N TariotBanner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix16Department of Psychiatry, University of Arizona, Phoenix.
Bradford C DickersonAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts9Frontotemporal Dementia Unit, Department of Neurology, Massachusetts General Hospital, Boston.
Reisa A SperlingDepartment of Neurology, Massachusetts General Hospital, Boston3Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts17Center for Alzheimer Research and Treatment, Departm.
Francisco LoperaGrupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia.
Eric M ReimanBanner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix16Department of Psychiatry, University of Arizona, Phoenix18Division of Neurogenomics, Translational Genomics Research Institute, Phoenix, Arizona.
Universidad de Antioquia · COArizona Alzheimer’s ConsortiumAthinoula A. Martinos Center for Biomedical Imaging · USWashington University in St. Louis · USAlzheimer's Association · USBoston University · USEli Lilly (United States) · USHarvard University · USMassachusetts Eye and Ear Infirmary · USMassachusetts General Hospital · USTranslational Genomics Research Institute · USUniversity of Arizona · US

Funding

THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
PET, APOE & the Preclinical Course of Alzheimer's DiseaseR01AG031581 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI CASELLI, RICHARD J., REIMAN, ERIC MICHAEL · 2008 to 2018
$16.6M
Alzheimer's Prevention InitiativeRF1AG041705 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2012 to 2012
$15.3M
Alzheimer's Prevention Initiative ADAD Colombia TrialR01AG055444 · NIA · BANNER HEALTH · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2017 to 2022
$14.9M
Memory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3M
Mentoring Imaging Research in Early ADK24AG035007 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SPERLING, REISA A. · 2010 to 2020
$1.4M
Notch and TGF-beta in the Control of Retinal Vascular IntegrityR00EY021624 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2014 to 2016
$736k
Notch and TGF-beta in the Control of Retinal Vascular IntegrityK99EY021624 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2012 to 2013
$177k
NEI NIH HHS EY021624NEI NIH HHS K99 EY021624NEI NIH HHS R00 EY021624NIA NIH HHS 2UF1 AG032438NIA NIH HHS K24 AG035007NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG19610NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG031581NIA NIH HHS R01 AG055444NIA NIH HHS RF1 AG041705NIA NIH HHS RF1AG041705NIA NIH HHS UF1 AG032438NIH HHS DP5 OD019833NIH HHS DP5OD019833
6 · The paper itself

Abstract

importanceBrain imaging and fluid biomarkers are characterized in children at risk for autosomal dominant Alzheimer disease (ADAD).

objectiveTo characterize and compare structural magnetic resonance imaging (MRI), resting-state and task-dependent functional MRI, and plasma amyloid-β (Aβ) measurements in presenilin 1 (PSEN1) E280A mutation-carrying and noncarrying children with ADAD. DESIGN, SETTING, AND

participantsCross-sectional measures of structural and functional MRI and plasma Aβ assays were assessed in 18 PSEN1 E280A carriers and 19 noncarriers aged 9 to 17 years from a Colombian kindred with ADAD. Recruitment and data collection for this study were conducted at the University of Antioquia and the Hospital Pablo Tobon Uribe in Medellín, Colombia, between August 2011 and June 2012. MAIN OUTCOMES AND MEASURES: All participants had blood sampling, structural MRI, and functional MRI during associative memory encoding and resting-state and cognitive assessments. Outcome measures included plasma Aβ1-42 concentrations and Aβ1-42:Aβ1-40 ratios, memory encoding-dependent activation changes, resting-state connectivity, and regional gray matter volumes. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to AD.

resultsSimilar to findings in adult mutation carriers, in the later preclinical and clinical stages of ADAD, mutation-carrying children were distinguished from control individuals by significantly higher plasma Aβ1-42 levels (mean [SD]: carriers, 18.8 [5.1] pg/mL and noncarriers, 13.1 [3.2] pg/mL; P < .001) and Aβ1-42:Aβ1-40 ratios (mean [SD]: carriers, 0.32 [0.06] and noncarriers, 0.21 [0.03]; P < .001), as well as less memory encoding task-related deactivation in parietal regions (eg, mean [SD] parameter estimates for the right precuneus were -0.590 [0.50] for noncarriers and -0.087 [0.38] for carriers; P < .005 uncorrected). Unlike carriers in the later stages, mutation-carrying children demonstrated increased functional connectivity of the posterior cingulate cortex with medial temporal lobe regions (mean [SD] parameter estimates were 0.038 [0.070] for noncarriers and 0.190 [0.057] for carriers), as well as greater gray matter volumes in temporal regions (eg, left parahippocampus; P < . 049, corrected for multiple comparisons). CONCLUSIONS AND RELEVANCE: Children at genetic risk for ADAD have functional and structural brain changes and abnormal levels of plasma Aβ1-42. The extent to which the underlying brain changes are either neurodegenerative or developmental remains to be determined. This study provides additional information about the earliest known biomarker changes associated with ADAD.

Indexed as

AdolescentAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersBrainBrain MappingChildFemaleHumansMagnetic Resonance ImagingMaleMutationOrgan SizePeptide FragmentsPresenilin-1Amyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersPeptide FragmentsPresenilin-1

Identifiers

PMID26121081
PMCPMC4625544
OpenAlexW2139484908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.